APGE · Apogee Therapeutics, Inc.
$135.07
+0.00% 2-day
End-of-day data · updated 2026-10-24
Market cap
$10B
Enterprise value
$9B
Trailing P/E
—
Forward P/E
-26.0
Dividend yield
—
Beta
0.33
Avg volume
3M
Employees
0K
Daily Change %
0.00%
5 Days Change
—
10 Days Change
—
30 Days Change
—
60 Days Change
—
Month to Day Change
0.00%
Year to Day Change
—
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Technical data is temporarily unavailable for APGE.
Analyst sentiment over time — APGE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-13
Latest call per bank · past 12 months
Deutsche Bank
Hold$135
-0.1% vs priceCitigroup
Neutral$135
-0.1% vs priceRBC Capital
Sector Perform$135
-0.1% vs priceUBS
Neutral$135
+0.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | Truist Securities | Maintains | Hold | $81.00 → $135 |
| 2026-08-12 | BTIG | Downgrade | Buy → Neutral | $0.00 |
| 2026-06-24 | Stifel | Downgrade | Buy → Hold | $133 → $135 |
| 2026-06-24 | TD Cowen | Downgrade | Buy → Hold | $0.00 |
| 2026-06-24 | Guggenheim | Downgrade | Buy → Neutral | $0.00 |
| 2026-06-24 | Mizuho | Downgrade | Outperform → Neutral | $110 → $135 |
| 2026-06-23 | Deutsche Bank | Downgrade | Buy → Hold | $116 → $135 |
| 2026-06-23 | Citigroup | Downgrade | Buy → Neutral | $125 → $135 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
APGE Price Chart
Loading chart for APGE…
Fundamentals
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.